Drugs / SCTB35
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06318884 | Apr 2024 → Oct 2026 expected | B-cell non-Hodgkin lymphoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06841042 | Feb 2025 → May 2027 expected | systemic lupus erythematosus | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07562022 | May 2026 → May 2028 expected | follicular lymphoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07570823 | May 2026 → Nov 2027 expected | diffuse large B-cell lymphoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTB35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07562022 ↗ |
| Route | Subcutaneous | “SCTB35 injection is subcutaneously given every week for the first 4 cycles, and thereafter every 3 weeks.” NCT06318884 ↗ |